Abstract
Background: The HERC family contains six members from HERC1 to HERC6 that are featured with the HECT domains that exerts ubiquitin ligase activity and the RCC1-like domains that are involved in cell cycle regulation. Although identified as early as 1990s, their biological functions are extensively studied in recent years. More and more researches have demonstrated that the HERC ubiquitin ligases are widely engaged in carcinogenesis, however, there lacks a comprehensive and instructive analysis.
Methods: The PubMed database was searched by keywords of individual HERC proteins (such as HERC4) and cancer. The emerging roles of HERC proteins in cancer and the specific mechanisms were collectively analyzed and discussed.
Results: HERC proteins belong to the HECT domain-containing ubiquitin ligases that can identify and mediate the ubiquitination of specific substrate proteins. All HERC ubiquitin ligases except HERC6 have been assigned one or more than one ubiquitination substrates. In all of HERCs, HERC1 and HERC2 have been widely studied, in contrast, there are no reported studies yet on protein ubiquitination mediated by HERC6. Dependent on the protein substrates, HERC proteins may act as a tumor suppressor or oncoprotein in specific cancer types. For example, HERC4 is believed to contribute to carcinogenesis of solid tumors such as lung cancer, but it suppresses the proliferation of myeloma cells.
Conclusion: HERC proteins as ubiquitin ligases are widely involved in various cancers. Targeting at specific HERC proteins could be a strategy for the treatment of certain cancers.
Keywords: HERC proteins, ubiquitin ligase, proteasomal degradation, cancer, tumor suppressor, oncoprotein.
Current Pharmaceutical Design
Title:The Emerging Roles of the HERC Ubiquitin Ligases in Cancer
Volume: 24 Issue: 15
Author(s): Xinliang Mao*, Gautam Sethi, Zubin Zhang and Qi Wang
Affiliation:
- Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, 12 Jichang Road, Baiyun District, Guangzhou 510405,China
Keywords: HERC proteins, ubiquitin ligase, proteasomal degradation, cancer, tumor suppressor, oncoprotein.
Abstract: Background: The HERC family contains six members from HERC1 to HERC6 that are featured with the HECT domains that exerts ubiquitin ligase activity and the RCC1-like domains that are involved in cell cycle regulation. Although identified as early as 1990s, their biological functions are extensively studied in recent years. More and more researches have demonstrated that the HERC ubiquitin ligases are widely engaged in carcinogenesis, however, there lacks a comprehensive and instructive analysis.
Methods: The PubMed database was searched by keywords of individual HERC proteins (such as HERC4) and cancer. The emerging roles of HERC proteins in cancer and the specific mechanisms were collectively analyzed and discussed.
Results: HERC proteins belong to the HECT domain-containing ubiquitin ligases that can identify and mediate the ubiquitination of specific substrate proteins. All HERC ubiquitin ligases except HERC6 have been assigned one or more than one ubiquitination substrates. In all of HERCs, HERC1 and HERC2 have been widely studied, in contrast, there are no reported studies yet on protein ubiquitination mediated by HERC6. Dependent on the protein substrates, HERC proteins may act as a tumor suppressor or oncoprotein in specific cancer types. For example, HERC4 is believed to contribute to carcinogenesis of solid tumors such as lung cancer, but it suppresses the proliferation of myeloma cells.
Conclusion: HERC proteins as ubiquitin ligases are widely involved in various cancers. Targeting at specific HERC proteins could be a strategy for the treatment of certain cancers.
Export Options
About this article
Cite this article as:
Mao Xinliang *, Sethi Gautam , Zhang Zubin and Wang Qi , The Emerging Roles of the HERC Ubiquitin Ligases in Cancer, Current Pharmaceutical Design 2018; 24 (15) . https://dx.doi.org/10.2174/1381612824666180528081024
DOI https://dx.doi.org/10.2174/1381612824666180528081024 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Oncohematology: From Bench to Bedside (Guest Editor: Vincenzo De Feo)]
Mini-Reviews in Medicinal Chemistry Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review
Current Drug Metabolism Lyn Regulates Cytotoxicity in Respiratory Epithelial Cells Challenged by Cigarette Smoke Extracts
Current Molecular Medicine Etoposide, Topoisomerase II and Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Ether Lipids as Anticancer Agents: Focus on Non-Phosphorus Cationic Glycerolipids
Mini-Reviews in Medicinal Chemistry Interferon-Alpha in the Treatment of Multiple Myeloma
Current Drug Targets Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Current Medicinal Chemistry Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Celecoxib in Cancer Therapy and Prevention – Review
Current Drug Targets Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Nuclear Imaging of Prostate Cancer with Gastrin-Releasing-Peptide- Receptor Targeted Radiopharmaceuticals
Current Pharmaceutical Design Deep Inspiration Breath-hold (DIBH) Technique to Reduce Cardiac Radiation Dose in the Management of Breast Cancer
Current Cancer Therapy Reviews Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Docetaxel (Taxotere) in the Treatment of Non-Small Cell Lung Cancer
Current Medicinal Chemistry Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer
Current Pharmaceutical Design Clinical Impact of Gene Expression Profiling on Oncology Diagnosis, Prognosis, and Treatment
Combinatorial Chemistry & High Throughput Screening